Valley wants our patients and community to be on the alert against medical billing scams. Learn how to protect yourself and your personal information from scammers posing as hospital representatives.
Read More
Evan H. Leibowitz, MD
Chief, Rheumatology, Valley Medical Group
- Specialties
-
Rheumatology
- Gender
-
Male
- Languages
-
English
Valley Medical Group
Member, ColigoCare
ColigoCare is a network of physicians working collectively to provide the highest quality care to patients and the community.
Location(s)
Valley Institute For Rheumatology & Autoimmune Diseases
1200 East Ridgewood Avenue
Suite 306 East
Ridgewood, NJ 07450
Phone: 201-389-0096
Fax: 201-857-8771
Education
- Education
-
NA, New York University College Of Dentistry, 1991 - 1992
MD, University Of Medicine And Dentistry Of New Jersey, 1992 - 1996
BA, Rutgers University, 1987 - 1991
- Fellowships
-
Hospital For Special Surgery, Rheumatology, 1999 - 2002
- Internship & Residency
-
New York Presbyterian Hospital, Internal Medicine, 1996 - 1999
- Board Certifications
-
Subspecialty Board Of Rheumatology - Certified, 2002
Get to Know Me
What are some of the specific conditions you treat?
Rheumatoid arthritis, systemic lupus, erythematosus, vasculitis, scleroderma, gout, polymyositis, dermatomyositis, sjogrens syndrome, pseudogout.
Techniques/Procedures:
Ultrasound-guided injections.
Describe some of your professional highlights.
New Jersey Rheumatology Association - President, 2015-2016
What would you like patients to know about your approach to care?
Rheumatology requires a close partnership between me and my patients. I listen closely to their symptoms, which helps to quickly make an accurate diagnosis. I strongly consider my patient's point of view with regards to coming up with treatment plans that they are comfortable with.
Awards & Accolades
Top Rheumatologist
Castle Connolly - New York Metro Area
2007-2015
Gold DOC Award
Arnold P. Gold Foundation
2011
Publications & Research
Clinical Trials
“A multicenter, open-label (Part A) followed by a randomized, double-blind, parallel-group, placebo-controlled study (Part B) to evaluate maintenance of remission in subjects with active axial spondyloarthritis (axSpA) receiving either Certolizumab pegol 200mg Q2W or 200mg Q4W as compared to placebo.”
This study is focused on treating patients with ankylosing spondylitis. We are looking for patients that are 45 or younger who have ankylosing spondylitis. All patients get treated with Cimzia for one year. Cimzia is already approved to treat the condition. If patients are doing well on the medication, (in remission), the medication will be withdrawn to see if they will stay in remission off of it. Patients will be monitored closely throughout the study.
Insurance
Valley Medical Group providers accept the following plans.
Patient Ratings & Comments
Comments are gathered from our patient satisfaction surveys.